Figure 3.

Boxplots analyzing the differences in overall survival according to the administered number of adjuvant Temozolomide cycles (1–5, 6, and 7–12) for different populations: patients with moderate vascularity and methylated MGMT (top left), patients with moderate vascularity and unmethylated MGMT (top right), patients with high vascularity and methylated MGMT (bottom left), and patients with high vascularity and unmethylated MGMT. * Significantly differences between groups (* in black). Data points beyond the whiskers are shown with + (in red).